LYS — Lysogene SA Income Statement
0.000.00%
Last trade - 00:00
HealthcareHighly SpeculativeMicro Cap
2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 3.59 | 13.4 | 13.4 | 3.73 |
Cost of Revenue | |||||
Gross Profit | -12.5 | -7.18 | -3.21 | -0.332 | -8.98 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 17.2 | 14.5 | 18.5 | 18.4 | 17 |
Operating Profit | -17.2 | -11 | -5.08 | -5.08 | -13.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -17.8 | -10.9 | -4.28 | -5.09 | -13.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -17.8 | -10.9 | -4.28 | -5.09 | -13.6 |
Net Income Before Extraordinary Items | |||||
Net Income | -17.8 | -10.9 | -4.28 | -5.09 | -13.6 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -17.8 | -10.9 | -4.28 | -5.09 | -13.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.52 | -0.869 | -0.315 | -0.322 | -0.807 |
Dividends per Share |